The EMA’s list included drugs made by some of the top generic drugmakers, including Teva Pharmaceutical Industries Ltd., Mylan NV and Novartis AG’s Sandoz.
The recommendation comes after the U.S. Food and Drug Administration (FDA) and the World Health Organization raised concerns about substitution and manipulation of patients’ clinical samples by Semler Research Centre Pvt Ltd.
The FDA asked drugmakers in April to repeat bioequivalence studies for drugs whose application used data obtained from tests conducted by Semler.
Generic drugmakers have to prove to health regulators through bioequivalence studies that their cheaper copycat drugs are as effective as the drug that they try to mimic.
The EMA review expressed concerns about the bioequivalence of the suspended generics of cancer drug erlotinib (Tarceva), migraine treatment eletripan and anti-malarial drug Atovaquone/Proguanil.
The EU health regulator says it also recommends against approving those drugs whose applications used data from studies conducted at the research site.
The agency, however, allowed sales of those drugs where the manufacturing company provided data from alternate studies.
The European Commission will make a legally binding decision on these recommendations, the agency says.